The objective of this task order is to obtain services for the development of contraceptive products intended for non-systemic delivery to determine, as appropriate, the efficacy, safety, toxicity,…
Ended Awarded Last action
- Contract number
- 75N94023F00003
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,372,326
Award facts
- Contract value 100% obligated
- $1,372,326.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $1,372,326 |
About this award
Sri International has been awarded a $1.37 million delivery order by the National Institute of Child Health and Human Development (NICHD) to provide research and development services for the development of contraceptive products intended for non-systemic delivery. The work involves determining efficacy, safety, toxicity, pharmacology, and pharmacokinetic and toxicokinetic properties of these contraceptive formulations. The contract is structured as a cost-plus-fixed-fee delivery order with an ultimate completion date of March 20, 2026, and carries no small business set-aside designation. Work will be performed at Sri International's Menlo Park, California location.
Sri International has engaged two subcontractors to support execution of this effort. Charles River Laboratories, Inc. was awarded a subcontract on August 9, 2024, to conduct a GLP tissue cross-reactivity study, while the University of Texas Medical Branch at Galveston received a subcontract on July 10, 2024, for evaluation of non-hormonal intravaginal rings in female sheep. These subcontracting arrangements leverage specialized laboratory and animal research capabilities to support the broader contraceptive product development objectives aligned with NICHD's mission to advance reproductive health research and interventions.
Description
The objective of this task order is to obtain services for the development of contraceptive products intended for non-systemic delivery to determine, as appropriate, the efficacy, safety, toxicity, pharmacology, and pharmacokinetic (PK) and toxicokin
Quick answers
Who was awarded contract 75N94023F00003?
75N94023F00003 was awarded to Sri International by National Institute of Child Health and Human Development (National Institutes of Health) on September 21, 2023.
How much is contract 75N94023F00003 worth?
The government has obligated $1,372,326 on 75N94023F00003.
Is contract 75N94023F00003 an order under another contract?
Yes. 75N94023F00003 is a delivery order under 75N94020D00003, an indefinite delivery contract.
Was contract 75N94023F00003 competed?
The extent of competition for 75N94023F00003 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award